

## Development of EGFR-targeting ADC candidate for the treatment of metastatic (late-stage) colorectal cancer

ProEn Therapeutics Inc.



ONCOLOGY	Candidate
Product Type	Recombinant Protein
Indication	Solid tumors that overexpress EGFR, especially metastatic colorectal cancer
Target	EGFR-overexpressing tumor cells compared to normal cells
MoA(Mechanism of Action)	The conjugated drug induces tumor cell death following highly selective binding of the Repebody to EGFR, which is overexpressed and densely clustered on the tumor cell surface.
Competitiveness	Leveraging the avidity effect, PRN201 selectively binds to tumor cells that overexpress EGFR, while sparing normal cells with low EGFR expression. This selective targeting enables potent anti-tumor efficacy even in KRAS-mutant cancers and minimizes off-target toxicity in normal tissues, offering a favorable therapeutic window compared to existing treatments.
Development Stage	Candidate
Route of Administration	Intravenous(IV)

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*